Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202464 | 0.81 | CPB2 (0.52) | CTSSCTSKEPHX1CPB2MEN1 | |
| SCHEMBL16945 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A | |
| SCHEMBL9742302 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A | |
| SCHEMBL9556128 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A | |
| SCHEMBL8283416 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A | |
| SCHEMBL482062 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A | |
| SCHEMBL9742291 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A | |
| SCHEMBL21427220 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A | |
| SCHEMBL21427213 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A | |
| SCHEMBL16946 | 0.78 | CTSK (0.70) | CTSSCTSKEPHX1CPB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | CTSS 132/4885CTSK 209/4885EPHX1 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.